No Data
Everbright Securities: Empowering commercial health insurance to promote payment diversification, medical insurance prepayment alleviates funding pressure.
After the implementation of the medical insurance prepayment system, it is expected to effectively alleviate the financial pressure of medical institutions in the corresponding areas, thereby improving the enterprise account payment status of pharmaceutical procurement and consumables channels, conducive to the overall development of the cash flow chain of medical institutions-pharmaceutical distribution-pharmaceutical manufacturing.
Jiangsu Hengrui Medicine Gets State Administrator Approval for Tumor Drug Clinical Trials
Jiangsu Hengrui Pharmaceuticals (600276.SH): received notification of approval for clinical trials of drugs.
Hengrui Pharmaceuticals (600276.SH) announced on November 8 that the company and its subsidiaries, Shandong Shengdi Pharmaceutical Co., Ltd., Chengdu Shengdi Pharmaceutical Co., Ltd., Shanghai Shengdi Pharmaceutical Co., Ltd., and Suzhou Shengdiya Biomedical Co., Ltd., have received the National Medical Products Administration's approval notice for clinical trials of HRS-2189 tablets, HRS-5041 tablets, HRS-1358 tablets, HRS-8080 tablets, SHR-8068 injections, Adebali monoclonal antibody injections, and HRS-6209 capsules, and will conduct clinical trials in the near future.
New Stock News | jiangsu hengrui pharmaceuticals (600276.SH) selected Citigroup and Morgan Stanley to lead the Hong Kong IPO.
A-share pharmaceutical leader jiangsu hengrui pharmaceuticals (600276.SH) is preparing for a Hong Kong IPO fundraising in 2025.
AVIC Securities: Pharmaceutical industry performance under pressure in the third quarter, total market value of heavyweight in fund holdings increased.
The demand for blood sector in biological products remains high, with vaccines facing sales pressure due to factors such as previous market consumption; active pharmaceutical ingredients are entering the tail end of downstream inventory, showing an improvement in demand, and future performance is expected to gradually improve.
Patient mortality risk reduced! Jiangsu Hengrui Pharmaceuticals (600276.SH) announced the latest clinical data of Ileticonazole liposomes.
Research results show that for patients with pancreatic cancer, the risk of death decreased by 37% with the combination of Erlotinib liposomes (II) compared to the control group.
No Data
No Data